Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAGI3 | Q5TCQ9 | 1/20 | 0.46 |
| ▸ | TASP1 | Q9H6P5 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | CASP4 | P49662 | 1/20 | 0.41 |
| ▸ | CASP5 | P51878 | 1/20 | 0.41 |
| ▸ | CASP9 | P55211 | 1/20 | 0.41 |
| ▸ | CASP6 | P55212 | 1/20 | 0.41 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.41 |
| ▸ | CASP10 | Q92851 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | ENPEP | Q07075 | 5/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20342185 | 0.89 | MAGI3 (0.44) | MAGI3TASP1CASP1CASP3CASP4 | |
| SCHEMBL20335574 | 0.88 | TASP1 (0.47) | MAGI3TASP1CASP1CASP3CASP4 | |
| SCHEMBL21515972 | 0.88 | TASP1 (0.47) | MAGI3TASP1CASP1CASP3CASP4 | |
| SCHEMBL20335572 | 0.88 | TASP1 (0.47) | MAGI3TASP1CASP1CASP3CASP4 | |
| SCHEMBL20342204 | 0.88 | TASP1 (0.47) | MAGI3TASP1CASP1CASP3CASP4 | |
| SCHEMBL20335576 | 0.88 | TASP1 (0.47) | MAGI3TASP1CASP1CASP3CASP4 | |
| SCHEMBL20335561 | 0.86 | TASP1 (0.46) | MAGI3TASP1CASP1CASP3CASP4 | |
| SCHEMBL20335563 | 0.86 | TASP1 (0.46) | MAGI3TASP1CASP1CASP3CASP4 | |
| SCHEMBL20342215 | 0.86 | TASP1 (0.46) | MAGI3TASP1CASP1CASP3CASP4 | |
| SCHEMBL20335565 | 0.86 | TASP1 (0.46) | MAGI3TASP1CASP1CASP3CASP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3405477-B1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2023-06-07 | — | — | EP | disclosed |
| US-11072634-B2 | Inhibitors of transglutaminases | ZEDIRA GMBH (DE) | 2021-07-27 | — | — | US | disclosed |
| US-20190322700-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2019-10-24 | — | — | US | disclosed |
| WO-2018122419-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2018-07-05 | — | — | WO | disclosed |
| EP-3342779-A1 | INHIBITORS OF TRANSGLUTAMINASES | Zedira GmbH (DE) | 2018-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190322700-A1 | INHIBITORS OF TRANSGLUTAMINASES | TGM2, TGM3, TGM1 | MAGI3 812/4885TASP1 670/4885CASP1 3068/4885 |
| US-11072634-B2 | Inhibitors of transglutaminases | TGM2, TGM3, TGM1 | MAGI3 812/4885TASP1 670/4885CASP1 3068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.